SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of
April 2007
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrants name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrants home country), or under the rules of the home
country exchange on which the registrants securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrants security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If Yes is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
|
210, 1167 Kensington Crescent N.W.
Calgary, Alberta
Canada T2N 1X7 |
FOR IMMEDIATE RELEASE
Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine
Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines
CALGARY, AB, April 17, 2007 - Oncolytics Biotech Inc. (Oncolytics) (TSX:ONC,
NASDAQ:ONCY) announces that a poster by Dr. Maureen E. Lane et al. of Cornell University, New York,
entitled In Vivo Synergy between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116
Xenografts is scheduled to be presented today at the American Association for Cancer Research
(AACR) Annual Meeting in Los Angeles, CA. The meeting runs from April 14-18, 2007.
The researchers found that treatment of human colon cancer cell lines with the combination of
REOLYSIN® and gemcitabine resulted in both in vitro and in vivo synergy. There was no
toxicity associated with the combined treatment. Tumours treated with the combination were
significantly smaller (by area and weight) than tumours in control groups or tumours treated with
either agent alone. The researchers concluded that the synergistic combination of
REOLYSIN® and gemcitabine is a promising therapeutic regimen for study in clinical
trials.
It is rare to see the virtual elimination of tumours as well as the long-lasting therapeutic
effect that we have observed from this study, said Dr. Brad Thompson, President and CEO of
Oncolytics. We are very encouraged by these results and look forward to testing this particular
treatment combination in our upcoming human systemic administration trial in the U.K.
The poster will be available on the Oncolytics website today at www.oncolyticsbiotech.com.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics clinical program includes a variety of Phase I and
Phase II human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com
This press release contains forward-looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
implication of the materials presented at this conference with respect to REOLYSIN®, the
Companys expectations related to the results of trials investigating delivery of
REOLYSIN®, and the Companys belief as to the potential of REOLYSIN® as a
cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the
Companys actual results to differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of funds and resources to pursue
research and development projects, the efficacy of REOLYSIN® as a cancer treatment, the
success and timely completion of clinical studies and trials, the Companys ability to successfully
commercialize REOLYSIN®, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the
Companys quarterly and annual filings with the Canadian and U.S. securities commissions for
additional information on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking statements. The Company
does not undertake to update these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
|
|
|
|
|
Oncolytics Biotech Inc.
|
|
The Equicom Group
|
|
The Investor Relations Group |
Cathy Ward
|
|
Nick Hurst
|
|
Erika Moran |
210, 1167 Kensington Cr NW
|
|
325, 300 5th Ave. SW
|
|
11 Stone St, 3rd Floor |
Calgary, Alberta T2N 1X7
|
|
Calgary, Alberta T2P 3C4
|
|
New York, NY 10004 |
Tel: 403.670.7377
|
|
Tel: 403.538.4845
|
|
Tel: 212.825.3210 |
Fax: 403.283.0858
|
|
Fax: 403.237-6916
|
|
Fax: 212.825.3229 |
cathy.ward@oncolytics.ca |
|
nhurst@equicomgroup.com |
|
emoran@investorrelationsgroup.com |
-30-